Search

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company, announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) [...]

Byline: Our Bureau Venus Remedies Ltd, a prominent oncology drug manufacturer, has secured marketing authorizations for two key cancer drugs, enhancing its global reach. The approvals include bortezomib in the [...]

2023 DEC 25 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Patients with newly diagnosed multiple myeloma (MM) who received daratumumab along with the standard [...]

ScinoPharm Taiwan has obtained U.S. abbreviated new drug application (ANDA) approval for its Bortezomib for Injection. This marks the company's first injection product developed and manufactured in-house, showcasing its capabilities [...]

A recent study from Tulane University explores the use of Bortezomib as a proteasome inhibitor in cancer therapy, particularly for multiple myeloma and mantle cell lymphoma. The research highlights the mechanisms of action of Bortezomib, such as inhibiting the 26S proteasome and modulating various cellular processes, while also acknowledging its limitations due to side effects like peripheral neuropathy and thrombotic microangiopathy. The study concludes by discussing the potential for next-generation proteasome inhibitors in cancer treatment. For more information, readers can refer to the article "Bortezomib In Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors" published in Life Sciences. [Extracted from the article]

The article from Reactions Weekly discusses two cases of patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) who did not respond to treatment with rituximab and unspecified steroids. One patient received alternative treatment with velcade, dexamethasone, and daratumumab and responded positively, while the other patient required dialysis before treatment and unfortunately passed away after 3.2 months. The article highlights the challenges in treating PGNMID and the importance of exploring different treatment options for patients who do not respond to initial therapies. [Extracted from the article]

A case report published in Reactions Weekly discusses a 55-year-old woman who experienced lack of efficacy during treatment with dexamethasone, daratumumab, and bortezomib for multiple myeloma. The woman developed leg edema two weeks after a COVID-19 infection, leading to hospitalization with renal dysfunction and the initiation of hemodialysis. Despite treatment, her renal function did not improve, and she subsequently experienced a decline in cardiac function, lactic acidosis, and hypotension. Ultimately, she passed away due to crystalglobulin-induced nephropathy and cardiac non-amyloid immunoglobulin deposition disease secondary to multiple myeloma. [Extracted from the article]

A 70-year-old woman experienced drug intolerance in the form of gastrointestinal side effects and weight loss while being treated with bortezomib for post-transplant lymphoproliferative disorder. She also showed lack of efficacy during treatment with daratumumab for the same disorder. Despite initially being suspected of having squamous cell carcinoma, she was diagnosed with PTLD and successfully treated with radiotherapy and immunosuppression reduction therapy. Subsequent treatments with daratumumab and bortezomib were adjusted, leading to resolution of lesions and no new lesions after rituximab treatment. [Extracted from the article]

A 67-year-old man with cryocrystalglobulinaemia (CCG) showed lack of efficacy during treatment with cyclophosphamide, bortezomib, and dexamethasone. Despite this treatment, his proteinuria persisted. Subsequent treatment with daratumumab led to improvement in serum creatinine and complete resolution of proteinuria 8 months after initial presentation. [Extracted from the article]

A 57-year-old woman developed neuropathy while being treated with bortezomib for IgG lambda monoclonal gammopathy of undetermined significance. She had a complex medical history, including cryoglobulinaemic vasculitis and granulomatosis with polyangiitis, and was initially on methotrexate and prednisone. After experiencing neuropathy, her treatment was switched to daratumumab in October 2023. [Extracted from the article]

The article in Reactions Weekly discusses eight case reports of patients with multiple myeloma who experienced various toxicities while undergoing treatment with cyclophosphamide, doxorubicin, carmustine, prednisone, or bortezomib. The patients developed severe side effects such as diarrhoea, nausea, mucositis, peripheral neuropathy, Aspergillus infection with viral co-infection, meningococcal sepsis, and Enterobacter sepsis, ultimately leading to their deaths. The study highlights the importance of monitoring and managing toxicities associated with antineoplastic treatments to improve patient outcomes. [Extracted from the article]

A 51-year-old woman with acute myeloid leukemia experienced lack of efficacy with various drug therapies, including ciclosporin, methotrexate, rituximab, dexamethasone, daratumumab, and bortezomib for post-transplant pure red cell aplasia. Despite receiving multiple treatments, she failed to achieve a haematological response and required continuous blood transfusions. Ultimately, she was successfully treated with graded doses of donor-type packed red blood cells transfusion and hydration, leading to sustained erythropoiesis and freedom from transfusions. [Extracted from the article]

A 73-year-old woman with multiple myeloma exhibited lack of efficacy during treatment with bortezomib, daratumumab, lenalidomide, and pomalidomide. Despite undergoing two autologous haematopoietic bone marrow transplants, she experienced disease progression, leading to relapse and the need for CAR-T-cell therapies. Complications such as bronchiectasis and Aspergillus infection were identified and treated with antibiotics and antifungal medication, along with immune-globulin therapy. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a real-world study of 2,212 patients diagnosed with multiple myeloma (MM) after 1 January 2018, et al. patient [age and sex not stated] was described, who exhibited lack of efficacy during treatment with daratumumab, bortezomib, thalidomide, and dexamethasone for MM [routes and dosages not stated]. [Extracted from the article]

A 57-year-old man experienced lack of efficacy during treatment with cyclophosphamide, bortezomib, and dexamethasone for proliferative glomerulonephritis. Despite being diagnosed with NK lymphocytosis and hypertension, his kidney function worsened, leading to the initiation of haemodialysis. The chemotherapy regimen was discontinued due to the lack of renal improvement, indicating ineffectiveness of the treatment. [Extracted from the article]

A 76-year-old woman with AL amyloidosis and multiple myeloma experienced various toxicities and lack of efficacy with different drug treatments. She developed symptoms such as fever, chills, hair loss, neurologic spells, fatigue, and neuropathy during treatment with daratumumab and carfilzomib. Despite trying multiple medications, including bortezomib, dexamethasone, selinexor, and prednisone, the woman faced challenges with efficacy and side effects. Ultimately, she found success with teclistamab after experiencing a range of responses and adverse reactions to different treatments. [Extracted from the article]

A 65-year-old man developed Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome while undergoing treatment for multiple myeloma with bortezomib and lenalidomide. Despite receiving mepolizumab, ciclosporin, and unspecified corticosteroids for DRESS syndrome, he exhibited lack of efficacy. After switching to benralizumab and upadacitinib, the man experienced rapid and near complete resolution of his dermatitis and peripheral eosinophilia. [Extracted from the article]

A study conducted at Virginia Commonwealth University explored the combined inhibition of ATR and MEK1/2 in promoting cell death in multiple myeloma (MM) cells. The research found that the dual dephosphorylation of STAT3 triggered by the inhibitors led to the downregulation of cytoprotective targets and MM cell death. This novel therapeutic strategy showed promise in MM treatment, improving survival in xenograft models with minimal toxicity. The study was funded by the NIH National Cancer Institute and published in the British Journal of Haematology. [Extracted from the article]

The article discusses the impact of the proteasome inhibitor, bortezomib, on the replication of Human cytomegalovirus (HCMV). The study shows that bortezomib reduces levels of viral genomes and infectious virions, affecting the expression of viral proteins involved in genome synthesis. The research suggests that proteasome inhibition disrupts HCMV replication by reducing the effective Multiplicity of Infection (MOI) to a level where only a fraction of infected cells can progress to fulminant infection. [Extracted from the article]

Researchers from the Laboratory of Physiopharmacology in Antwerp, Belgium, conducted a study on the effects of proteasome inhibitors, specifically carfilzomib and bortezomib, on cardiac function, arterial stiffness, and vascular reactivity. The study, which involved male mice, found that short-term treatment with these inhibitors did not significantly impact arterial stiffness but did show a steeper pressure-stiffness curve with carfilzomib. Additionally, carfilzomib was associated with a decrease in left ventricular ejection fraction in hypertensive mice. Overall, the study concluded that the short-term use of carfilzomib and bortezomib was relatively safe for the protocols assessed. [Extracted from the article]

The article focuses on the FDA (Food and Drug Administration) approval of isatuximab-irfc (Sarclisa) with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, based on improved progression-free survival in the IMROZ trial.

A retrospective study involving 185 patients described five individuals (4 men, 1 woman) aged 60-68 who developed pulmonary thromboembolism, deep vein thrombosis, or superficial vein thrombosis while being treated for multiple myeloma with various drugs. Four out of the 5 patients also showed lack of efficacy when treated with aspirin for venous thromboembolism prophylaxis. Medical history of diabetes or hypertension was noted in four of the patients. The study highlighted potential complications and lack of effectiveness of certain treatments in this patient population. [Extracted from the article]

A 69-year-old man with IgG kappa multiple myeloma experienced a lack of efficacy with daratumumab, pomalidomide, and dexamethasone treatment, leading to disease progression. He also developed pharyngeal discomfort and dysphonia while receiving pentamidine. Despite treatment with tranexamic-acid for laryngeal oedema, he did not show improvement, eventually requiring a tracheostomy. However, at his two-month follow-up, he reported being asymptomatic with improved voice and stable respiratory function. [Extracted from the article]

A patent has been issued for modulating the GABARAP gene to induce immunogenic cell death in cancer cells, particularly in hematological cancers like multiple myeloma. The patent, assigned to Dana-Farber Cancer Institute Inc., highlights the importance of combining immunotherapy with chemotherapy to enhance the immune response against cancer cells. The invention focuses on increasing the expression of GABARAP and calreticulin, as well as decreasing the expression of STC1, to improve the efficacy of cancer treatments. This innovative approach aims to address the challenges of intrinsic resistance to immunotherapy and enhance patient outcomes in cancer treatment. [Extracted from the article]

A 67-year-old man with multiple myeloma developed movement and neurocognitive toxicity, pneumonia, infections, and other toxicities following treatment with various drugs. Despite multiple lines of therapy, including CAR-T cell treatment, the man experienced lack of efficacy and toxicities, ultimately leading to his death. The toxicities were considered secondary to the treatments received for his multiple myeloma, highlighting the complex nature of managing such conditions. [Extracted from the article]

The article from Reactions Weekly discusses two case reports of elderly patients with chronic lymphocytic leukaemia (CLL) who exhibited lack of efficacy during treatment with various drugs. In the first case, a woman with CLL did not respond to daratumumab and eventually died due to disease progression. In the second case, a patient with CLL and breast cancer experienced worsening clinical condition despite treatment with multiple drugs, leading to death from disease progression. [Extracted from the article]

A 54-year-old woman with Turner's syndrome and hypothyroidism developed myocardial injury while being treated with bortezomib for monoclonal light chain deposition disease. Despite receiving clopidogrel for thromboembolism prophylaxis, she experienced a lack of efficacy, leading to a cerebrovascular accident. Treatment with bortezomib, cyclophosphamide, and dexamethasone was discontinued, and she was successfully treated with daratumumab and steroids for focal crescentic glomerulonephritis secondary to the disease. [Extracted from the article]

A study from 2009 to 2022 reported on 8 patients who experienced lack of efficacy during immunosuppression with tacrolimus and mycophenolic-acid for liver transplant rejection prophylaxis. These patients, diagnosed with various conditions like cirrhosis and hepatocellular carcinoma, underwent liver transplantation but developed antibody-mediated rejection despite therapy. Treatment with immune-globulin, methylprednisolone, bortezomib, rituximab, or steroids was attempted, with varying outcomes including chronic rejection and re-transplantation for some patients. One patient ultimately passed away, but the majority saw resolution of their rejection. [Extracted from the article]

A 67-year-old man developed tremors while being treated with cotrimoxazole for Pneumocystis jirovecii pneumonia. He had a history of multiple myeloma, stem-cell transplantation, and ongoing lenalidomide treatment. The tremors appeared shortly after starting cotrimoxazole and improved with a reduction in dosage. The man completed his treatment without further adverse events. [Extracted from the article]

A 62-year-old woman experienced severe heart failure while being treated with bortezomib for multiple myeloma and cardiac amyloidosis. Despite receiving dopamine and norepinephrine for heart failure, she showed lack of efficacy. The woman had various symptoms, including anorexia, asthenia, and gastrointestinal upset, and was ultimately discharged home against medical advice in critical condition. The treatment with bortezomib led to bradycardia and first-degree atrioventricular block, indicating severe heart failure. [Extracted from the article]

An 81-year-old woman with a history of various medical conditions experienced lack of efficacy during treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone for light chain (AL) amyloidosis and chylothorax. Despite receiving multiple medications, including diuretics, her symptoms worsened, leading to recurrent pleural effusions. After undergoing hospitalization and various procedures, she was eventually treated with octreotide, which successfully resolved the pleural effusions. However, she experienced worsening kidney function, requiring haemodialysis, and her cyclophosphamide therapy was discontinued. [Extracted from the article]

A new study conducted by researchers at Cooper Medical School of Rowan University in Camden, New Jersey, explores the potential of a selective Mcl-1 inhibitor called KS18 to treat multiple myeloma (MM) and overcome treatment resistance. The study found that KS18 effectively induces cell death in MM by targeting the Mcl-1 protein through dual regulatory mechanisms. It also demonstrated that KS18 can synergize with other drugs to boost apoptosis and overcome resistance. The research suggests that KS18 may provide new hope for MM patients experiencing recurrence or resistance. [Extracted from the article]

2023 SEP 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Peripheral Neuropathy have been published. According to news [...]

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, a privately-held, leading international pharmaceutical company, announced that the United Kingdom's (UK) Medicines and Healthcare [...]

A 51-year-old man with Waldenstrom's macroglobulinaemia experienced multiple toxicities and lack of efficacy while undergoing treatment with bortezomib, dexamethasone, rituximab, cyclophosphamide, and ibrutinib. He developed reactivation of herpes simplex type 1, malignant syphilis, and Giardia intestinalis enteritis. Reactivation of herpes simplex type 1 was attributed to the combination therapy, while malignant syphilis and Giardia intestinalis enteritis were determined to be related to the same treatment. The patient received appropriate treatment for each condition and did not report any new infectious complications two years later. [Extracted from the article]

This article discusses three case reports of women who developed posterior reversible encephalopathy syndrome (PRES) or drug intolerance while undergoing treatment for myeloma. The first case involved a 73-year-old woman who experienced symptoms such as headaches, nausea, and confusion, which were attributed to her treatments. She underwent management for PRES and experienced progressive neurological recovery. The second case involved a 62-year-old woman who experienced symptoms such as headaches and hallucinations, which were also linked to her treatments. She achieved complete clinical recovery and resumed her myeloma treatment. The third case involved a 53-year-old woman who experienced symptoms such as drowsiness and confusion, which were attributed to her treatments. She showed rapid clinical recovery and resumed her myeloma treatment. [Extracted from the article]

An elderly man developed a skin rash while being treated for multiple myeloma with bortezomib and dexamethasone. He also experienced lymphocytopenia during treatment with elotuzumab and lenalidomide for multiple myeloma, and lack of efficacy during treatment with rifampicin, ethambutol, and clarithromycin for disseminated non-tuberculous mycobacteria (NTM) infection, remdesivir for COVID-19, and piperacillin/tazobactam for hospital-acquired pneumonia. Despite receiving various treatments, including antibiotics and antivirals, the man's respiratory condition did not improve, and he passed away due to hospital-acquired pneumonia and disseminated NTM infection. [Extracted from the article]

A 54-year-old woman with relapsed and refractory multiple myeloma (MM) experienced grade 2 local cytokine release syndrome (CRS) during treatment with idecabtagene-vicleucel. She also showed a lack of efficacy with various other treatments for MM, including elotuzumab, lenalidomide, pomalidomide, daratumumab, carfilzomib, doxorubicin, and bortezomib. Despite these challenges, the woman achieved complete remission of MM after receiving dexamethasone for CRS and relapsed/refractory MM. The grade 2 local CRS was believed to be a result of idecabtagene-vicleucel treatment. [Extracted from the article]

A 55-year-old man with multiple myeloma (MM) experienced lack of efficacy during treatment with daratumumab, thalidomide, bortezomib, and dexamethasone. He also developed psoriasis while being treated with lenalidomide for refractory MM. The patient's medications were adjusted accordingly, and his cutaneous rash was successfully treated with glucocorticoids and narrowband ultraviolet B phototherapy. This case highlights the potential adverse reactions and lack of efficacy associated with certain antineoplastic drugs in the treatment of MM. [Extracted from the article]

In a retrospective study involving 80 patients, a case was described where an adult patient with multiple myeloma exhibited lack of efficacy during treatment with bortezomib, daratumumab, dexamethasone, and thalidomide. The patient received a combination of these drugs, but after two cycles of treatment, disease progression was observed. This case highlights the need for further research and alternative treatment options for patients with multiple myeloma. [Extracted from the article]

A 66-year-old man with multiple health conditions, including metabolic syndrome, chronic ischaemic heart disease, and aortic stenosis, was diagnosed with amyloid light chain (AL) amyloidosis. He underwent treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone, but experienced poor tolerance and lack of efficacy. The treatment worsened his symptoms and led to complications such as intercurrent infections and continuous decompensation of heart failure. Unfortunately, the man eventually died due to decompensated heart failure. [Extracted from the article]

A 63-year-old diabetic man with non-secretory multiple myeloma (NSMM) experienced a lack of efficacy during treatment with dexamethasone, bortezomib, and thalidomide. He initially presented with various symptoms and was eventually diagnosed with NSMM, leading to the initiation of the aforementioned treatment. However, he developed necrotic dermatohypodermia after the first cycle and his condition rapidly deteriorated over 15 days, progressing to plasma acute leukemia. Despite treatment, the patient had a poor outcome, indicating a lack of efficacy with the prescribed medications. [Extracted from the article]

In a retrospective study of 374 patients with POEMS syndrome, five patients were identified who did not respond to various drug treatments. Case 1 involved a patient who did not respond to daratumumab and dexamethasone but later achieved stability with carfilzomib, pomalidomide, and dexamethasone. Case 2 described a patient who did not respond to multiple treatment regimens and eventually passed away. Case 3 involved a patient who did not respond to daratumumab, pomalidomide, bortezomib, and dexamethasone. Case 4 described a patient who did not respond to carfilzomib, lenalidomide, and dexamethasone but achieved a complete response with daratumumab, pomalidomide, and dexamethasone. Case 5 involved a patient who did not respond to pomalidomide and dexamethasone but achieved a complete response with carfilzomib and dexamethasone. [Extracted from the article]

Researchers at Warsaw Medical University have conducted a review on the mechanisms of action of proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM) and how MM cells develop resistance to these drugs. The review explores various strategies to overcome PI resistance, including new inhibitors of the ubiquitin-proteasome system, drug efflux inhibitors, autophagy disruption, targeting stress response mechanisms, affecting survival and cell cycle regulators, bone marrow microenvironment modulation, and immunotherapy. Some of these strategies have already led to the development of new anti-MM medications. The researchers hope that further exploration of these strategies will expand therapeutic options and improve patient outcomes. [Extracted from the article]

The article discusses a Phase 1b/2a trial of duvelisib combined with romidepsin for relapsed or refractory T-cell lymphomas. Researchers at Memorial Sloan-Kettering Cancer Center found that the combination was more effective and had lower toxicity compared to duvelisib with bortezomib, suggesting it as a promising treatment option for T-cell lymphomas. Topics include the efficacy of combined PI3K and HDAC inhibition, safety profiles of treatments, and clinical response rates.

The article from Karl Landsteiner University of Health Sciences explores the dual targeting of MYC and JUNB transcriptional programs to enhance anti-myeloma activity. The study demonstrates that MYC and JUNB operate through distinct transcriptional pathways and that targeting both with MZ-1 and JUNB inhibitors synergistically improves multiple myeloma cell death. Topics include: MYC and JUNB transcriptional targeting, multiple myeloma therapy, and cancer treatment strategies.

A recent study conducted in Uttar Pradesh, India, evaluated the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. The researchers optimized a nanoformulation using Box-Behnken Design and validated the method according to US-FDA guidelines. The size of the nanoformulation was found to be 133.9 +/- 1.97 nm, with promising pharmacokinetic results showing higher C-max for PTX-BTZ-NE compared to free PTX-BTZ. The study suggests that these findings could contribute to the treatment of breast cancer using PTX and BTZ. [Extracted from the article]

A recent study conducted at the H. Lee Moffitt Cancer Center in Tampa, Florida, has made significant progress in the treatment of multiple myeloma (MM). The researchers developed a pipeline to identify potential targets for MM immunotherapy and found that LILRB4, an immunoreceptor, emerged as a promising candidate. They developed Chimeric Antigen Receptor (CAR) T-cells targeting LILRB4, which were found to be effective in killing MM cells in vitro. This research suggests that LILRB4 could be a viable therapeutic target for MM patients, particularly those at high risk. Ongoing studies are investigating the role of LILRB4 in the interaction between MM and immune cells. [Extracted from the article]

A retrospective study involving 973 patients between January 2017 and December 2022 reported two cases of patients developing severe diarrhea while being treated with bortezomib or ixazomib for unspecified cancer. The patients, whose ages and genders were not disclosed, experienced grade 4 diarrhea with bortezomib and grade 3 diarrhea with ixazomib, as per the common terminology criteria for adverse events (CTCAE). Specific details such as dosages, routes of administration, durations of treatment, and outcomes were not provided in the study. [Extracted from the article]